2篇
您的检索式：作者名="Zaid Tafesh"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of anti-hepatic fibrosis drugs显示文摘Recent progress in our understanding of the pathways linked to progression from hepatic insult to cirrhosis has led to numerous novel therapies being investigated as potential cures and inhibitors of hepatic fibrogenesis. Liver cirrhosis is the final result of prolonged fibrosis, which is an intimate balance between fibrogenesis and fibrinolysis. A number of these complex mechanisms are shared across the various etiologies of liver disease. Thankfully, investigation has yielded some promising results in regard to reversal of fibrosis, particularly the indirect benefits associated with antiviral therapy for the treatment of hepatitis B and C and the farnesoid receptor agonist for the treatment of primary biliary cholangitis and metabolic associated fatty liver disease. A majority of current clinical research is focused on targeting metabolic associated fatty liver disease and its progression to metabolic steatohepatitis and ultimately cirrhosis, with some hope of potential standardized therapeutics in the near future. With our ever-evolving understanding of the underlying pathophysiology, these therapeutics focus on either controlling the primary disease(the initial trigger of fibrogenesis), interrupting receptor ligand interactions and other intracellular communications, inhibiting fibrogenesis, or even promoting resolution of fibrosis. It is imperative to thoroughly test these potential therapies with the rigorous standards of clinical therapeutic trials in order to ensure the highest standards of patient safety. In this article we will briefly review the key pathophysiological pathways that lead to liver fibrosis and present current clinical and experimental evidence that has shown reversibility of liver fibrosis and cirrhosis, while commenting on therapeutic safety. | Konstantinos Damiris Zaid H Tafesh Nikolaos Pyrsopoulos | 2020 | World Journal of Gastroenterology2020，26，41： | 8 |
| 2 | Trends in hospitalization for alcoholic hepatitis from 2011 to 2017:A USA nationwide study显示文摘BACKGROUND Severe alcoholic hepatitis(AH)is one of the most lethal manifestations of alcoholassociated liver disease.In light of the increase in alcohol consumption worldwide,the incidence of AH is on the rise,and data examining the trends of AH admission is needed.AIM To examine inpatient admission trends secondary to AH,along with their clinical outcomes and epidemiological characteristics.METHODS The National Inpatient Sample(NIS)database was utilized,and data from 2011 to 2017 were reviewed.We included individuals aged≥21 years who were admitted with a primary or secondary diagnosis of AH using the International Classification of Diseases(ICD)-9 and its correspondent ICD-10 codes.Hepatitis not related to alcohol was excluded.The national estimates of inpatient admissions were obtained using sample weights provided by the NIS.RESULTS AH-related hospitalization demonstrated a significant increase in the USA from 281506(0.7%of the total admission in 2011)to 324050(0.9%of the total admi-ssion in 2017).The median age was 54 years.The most common age group was 45–65 years(range 57.8%–60.7%).The most common race was white(63.2%–66.4%),and patients were predominantly male(69.7%–71.2%).The primary healthcare payers were Medicare(29.4%–30.7%)and Medicaid(21.5%–32.5%).The most common geographical location was the Southern USA(33.6%–34.4%).Most patients were admitted to a tertiary care center(50.2%–62.3%)located in urban areas.Mortality of AH in this inpatient sample was 5.3%in 2011 and 5.5%in 2017.The most common mortality-associated risk factors were acute renal failure(59.6%–72.1%)and gastrointestinal hemorrhage(17.2%–20.3%).The total charges were noted to range between$25242.62 and$34874.50.CONCLUSION The number of AH inpatient hospitalizations significantly increased from 2011 to 2017.This could have a substantial financial impact with increasing healthcare costs and utilization.AH-mortality remained the same. | Ali Wakil Mujtaba Mohamed Zaid Tafesh Mumtaz Niazi Raquel Olivo Weiyi Xia Patricia Greenberg Nikolaos Pyrsopoulos | 2022 | World Journal of Gastroenterology2022，28，34： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员